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306Objective: Our objective was to compare off-pump coronary artery bypass surgery carried out via a left antero-
lateral thoracotomy (ThoraCAB) or via a conventional median sternotomy (OPCAB).
Background:Recent advances in minimally invasive cardiac surgery have extended the technique to allow com-
plete surgical revascularization on the beating heart via thoracotomy.
Methods: Patients undergoing nonemergency primary surgery were enrolled between February 2007 and Sep-
tember 2009 at 2 centers. The primary outcome was the time from surgery to fitness for hospital discharge as
defined by objective criteria.
Results: A total of 93 patients were randomized to off-pump coronary artery bypass surgery via a median ster-
notomy (OPCAB) and 91 to off-pump coronary artery bypass surgery via a left anterolateral thoracotomy
(ThoraCAB). The surgery was longer for patients in the ThoraCAB group (median, 4.1 vs 3.3 hours) and there
were fewer with more than 3 grafts (2% vs 17%). The median time from surgery to fitness for discharge was 6
days (interquartile range, 4-7) in the ThoraCAB group versus 5 days (interquartile range, 4-7) in the OPCAB
group (P ¼ .53). The intubation time was shorter, by on average 65 minutes, in the ThoraCAB group
(P ¼ .017), although the time in intensive care was similar (P ¼ .91). Pain scores were similar (P ¼ .97), but
more analgesia was required in the ThoraCAB group (median duration, 38.8 vs 35.5 hours, P<.001; tramadol
use, 66% vs 49%, P ¼ .024). ThoraCAB was associated with significantly worse lung function at discharge
(average difference,0.25 L, P ¼ .01) but quality of life scores at 3 and 12 months were similar (P ¼ .52).
The average total cost was 10% higher with ThoraCAB (P ¼ .007).
Conclusions: ThoraCAB resulted in no overall clinical benefit relative to OPCAB. (J Thorac Cardiovasc Surg
2013;146:306-16)Supplemental material is available online.Earn CME credits at
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The Journal of Thoracic and Cardiovascular SurgMinimally invasive cardiac surgery (MICS) aims to reduce
the inflammatory response, organ dysfunction, and morbid-
ity attributable to surgical access, cardiopulmonary bypass
(CPB), and manipulation of the aorta, while achieving com-
plete revascularization. Minimally invasive direct coronary
artery bypass (MIDCAB) via a left anterior small thoracot-
omy represented a milestone development, conferring the
survival benefit of the left internal thoracic artery to the
left anterior descending artery while avoiding sternotomy
and CPB.1-3 The technique was then extended to patients
with multivessel disease by combining MIDCAB with
percutaneous coronary intervention to non–left anterior
descending artery vessels to provide truly minimally
invasive hybrid multivessel revascularization.4,5 However,
hybrid procedures were only possible in selected patients
with favorable anatomy. Moreover, logistical issues
remained, and the reintervention rate was high.6-8 Rather,
MIDCAB led to renewed interest in off-pump coronary ar-
tery bypass (OPCAB) where complete revascularization
could be achieved without CPB and often without aortic
manipulation, albeit via a sternotomy incision.9,10 Inery c August 2013
Abbreviations and Acronyms
CABG ¼ coronary artery bypass graft
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
FEV1 ¼ forced expiratory volume after 1
second
FVC ¼ forced vital capacity
IL ¼ interleukin
MICS ¼ minimally invasive cardiac surgery
MIDCAB ¼ minimally invasive direct coronary
artery bypass
OPCAB ¼ off-pump coronary artery bypass
surgery via a median sternotomy
RCT ¼ randomized controlled trial
SIRS ¼ systemic inflammatory response
syndrome
ThoraCAB ¼ off-pump coronary artery bypass
surgery via a left anterolateral
thoracotomy
TR ¼ time ratio
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Drandomized controlled trials (RCTs), OPCAB reduced the
inflammatory response and severity of organ injury and
used fewer health care resources,11 with equivalent long-
term graft patency, quality of life, and survival compared
with coronary artery bypass grafting (CABG) with
CPB.12,13
The increasingly high-risk population referred for sur-
gery, the morbidity associated with sternotomy, economic
considerations, and the desires of patients for less postoper-
ative pain and a quicker return to normal living have led to
pressure to further refine MICS techniques. To extend the
advantages of OPCAB, several groups have developed
a technique whereby complete revascularization may be
performed on the beating heart through a lateral thoracot-
omy incision (ThoraCAB) with minimal morbidity and
rapid hospital discharge.14-16 Concerns remain, however,
as to whether in unselected patients technical precision
may be compromised3 or whether excessive rib retraction
may result in increased postoperative pain.17 We carried
out an RCT to evaluate whether ThoraCAB represents
a clinical benefit beyond that conferred by OPCAB.
METHODS
Study Design
A 2-center, open, parallel-group RCT (ISRCTN 77366282) was used.
Participants
Participants included adults (>16 years and<80 years) undergoing non-
emergency primary CABG on the beating heart without the use of CPB and
cardioplegic arrest. Patients who had undergone heart or lung surgery pre-
viously or for whom the surgeon was unwilling to carry out the surgery via
either method were excluded.The Journal of Thoracic and CaStudy Settings
The study was conducted at the Bristol Heart Institute, Bristol (United
Kingdom) and Ospedale Pasquinucci, Massa Carrara (Italy), 2 specialized
regional cardiac surgery centers. Three surgeons, 2 in Bristol and 1 in Italy,
participated. The study was approved by the Southmead Research Ethics
Committee (ref. 07/Q2002/53) and by the Comitato Etico Locale of the
Ospedale Pasquinucci (protocol number 150).
Interventions
Patients were randomized to CABG on the beating heart through either
a median sternotomy (OPCAB, control) or a left anterolateral thoracotomy
(ThoraCAB, experimental). OPCAB was carried out as described previ-
ously9 with subsequent modifications subsumed into the current standard
protocol, for example, use of an intracoronary shunt when performing a dis-
tal anastomosis. ThoraCAB, and associated anesthetic technique, was car-
ried out as described by Guida and colleagues.14 With the left side of the
patient elevated to approximately 30, an anterolateral incision is made
on the fourth or fifth intercostal space from the midclavicular to the anterior
axillary line, sparing the latissimus dorsi. The left lung is usually deflated;
if single lung ventilation is not possible, the left lung is gently compressed
using a laparotomy sponge. The left internal thoracic artery is harvested un-
der direct vision. The pericardium is incised from the pulmonary artery to-
ward the ascending aorta and then toward the right atrial appendage.
Traction sutures are positioned on the pericardium to rotate the ascending
aorta to the right side. Proximal graft anastomoses on the aorta are per-
formed first with a side-biting clamp in the conventional way. The pericar-
dium is then incised parallel to the left phrenic nerve to expose the posterior
and lateral wall vessels. Distal anastomoses are performed with an Octopus
stabilizer (Medtronic Inc, Minneapolis, Minn) and intracoronary shunt.
Postoperative management was in accordance with institution-specific
protocols. A protocol for postoperative pain relief for ThoraCAB patients
was written by cardiac anesthetists and intensivists in Bristol. A policy
of early extubation was adopted for all patients. For ThoraCAB patients,
at the time of wound closure the surgeon sutured in place a paravertebral
catheter to provide a paravertebral block (infusion of 0.125% bupivacaine,
5-10 mL/h); a 15- to 20-mL loading bolus of 0.25% bupivacaine through
the catheter and injections into the intercostal spaces (0.125% bupivacaine)
were also given before chest closure. Pain relief in the event of failure of the
paravertebral catheter included the following: (1) local analgesia, intercos-
tal blocks, up to 6 spaces injecting 5 mL 0.125% bupivacaine into each
space, repeated 4 to 6 hourly if required; (2) adjuvant analgesia, intrave-
nous ketoralac/diclofenac (up to 30 mg); (3) adjuvant analgesia, nurse ad-
ministered intravenous morphine (up to 5-mg boluses); and (4) adjuvant
analgesia, intravenous ketamine infusion (1.5-3 mg $ kg1 $ min1). All pa-
tients had patient-controlled analgesia.
Outcome Measures
Primary outcome. The primary outcome was the number of days
from surgery until fit for discharge from the hospital. Patients were classi-
fied fit when (1) the chest x-ray film was clear with no evidence of pleural
effusion requiring drainage, lung collapse/consolidation, or pneumothorax,
(2) there was no suspected infection, (3) routine blood test results and tem-
perature were normal, and (4) the patient was physically fit.
The definition was modified partway through the trial after feedback
from the independent Data Monitoring and Safety Committee. Initially,
components 3 and 4 were not included. These data were collected retro-
spectively for the Bristol patients recruited before the change but were
not available for the Italian patients. The definitions applied to minimize
the susceptibility to detection bias are described in Appendix E1.
Secondary outcomes. Secondary outcomes were as follows: (1) the
patient’s judgment about his or her readiness for discharge; (2) biochemical
inflammatory markers, that is, complement activation (C3a and C5) and in-
terleukin (IL-6, IL-8, and IL-10)18 assessed preoperatively, at the end of the
operation, and 4, 12, and 24 hours postoperatively; (3) pulmonary functionrdiovascular Surgery c Volume 146, Number 2 307
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Dtests at recruitment and discharge; (4) pain scores measured with a 10-cm
visual analog scale at 2, 12, 24, and 36 hours after extubation and on dis-
charge; (5) the total volume and dose of local anesthetic (paravertebral
block), patient-controlled analgesia, and other intravenous analgesia ad-
ministered; use of nonsteroidal anti-inflammatory or opioid drugs; (6)
length of intensive care unit and postoperative hospital stay; (7) in-
hospital mortality and other standard measures of morbidity as used in pre-
vious RCTs9; (8) including ASEPSIS* at 6 weeks postoperatively19; (9)
use of health care resources and associated costs; and (10) quality of life
at recruitment and 3 and 12 months after surgery, measured using the cor-
onary revascularization outcome questionnaire.20 Pulmonary function tests
included peak expiratory flow rate, forced vital capacity (FVC), forced ex-
piratory volume after 1 second (FEV1) and the FEV1/FVC ratio. If a patient
was unable to use the visual analog scale, a verbal response was requested.
Costs associatedwith health care resource use included staffing and over-
heads (1) in the theater for the duration of the operation, (2) during the inten-
sive care, high dependency, and postoperative ward stay, (3) additional
operative interventions to treat complications, and (4) readmissions. Costs
were limited to the perspective of the United KingdomNational Health Ser-
vice; information was not collected from participants (see Appendix E1).
Data onpulmonary function, postdischargewound infections, andquality
of lifewere collected for theBristol patients only.Biochemical inflammatory
markers were assessed in a consecutive subsample of 60 Bristol patients.
Sample Size
Inasmuch as no published data existed for time until fit for discharge, infor-
mation about total postoperative hospital stay was used as a proxy. The 2
published case series for ThoraCAB reported 63% discharged within 4
days15 and 65% dischargedwithin 2 days.14 Themedian postoperative stayaf-
terOPCAB inBristol was 6 days, with 69% dischargedwithin 7 days.We sus-
pected that the ThoraCAB data were optimistic and so set the sample size to
detectmedian timesuntil fit for discharge of 3 and5 days, respectively (assum-
ing time until fit for discharge would be shorter, on average, than the total
postoperative stay). A study of 180 patients (90 per group) had 90% power
to detect this difference (hazard ratio, 1.65) with 5% significance (2-tailed).
Randomization
Randomized treatment allocations were computer generated.21 Alloca-
tions were stratified by center and cohort minimization was used to ensure
balance for the number of diseased vessels, diabetic status, and surgeon.
Patients were assigned in a 1:1 ratio. The Internet-based system was pass-
word protected and allocations were concealed until data to uniquely iden-
tify the patient and confirm eligibility had been entered.
Statistical Methods
The time until fit for discharge was determined from the individual fit-
ness criteria. A patient was classified fit on the earliest date after surgery
when all the criteria were met (and no component event subsequently re-
curred before discharge). If any of the component events were not ‘‘re-
solved’’ during the patient’s postoperative hospital stay (ie, the patient
was discharged with 1 ‘‘event’’ or more present), then the patient’s fitness
was censored at the time of discharge from the cardiac unit. Similarly, if at
least 1 of the criteria was not met before discharge and was not subse-
quently reassessed, then the outcome was censored at the time of this
last assessment. For patients recruited in Italy before the fitness definition
was changed, the actual length of postoperative hospital stay was used. If
the time to extubation or discharge was not observed because the patient
died, the outcome was censored at death.*ASEPSIS ¼ Additional treatment, the presence of Serous discharge, Erythema, Pu-
rulent exudate, and Separation of the deep tissues, the Isolation of bacteria, and the
duration of inpatient Stay.
308 The Journal of Thoracic and Cardiovascular SurgAnalyses were carried out on the basis of intention to treat. Continuous
variables were summarized using the mean and standard deviation (or me-
dian and interquartile range if the distribution was skewed), and categorical
data were summarized as a number and percentage. All comparisons of out-
comes between the OPCAB and ThoraCAB patients were adjusted for fac-
tors included in the cohort minimization. Results are presented as effect
sizes with 95% confidence intervals (CIs).
One subgroup analysis, comparing the primary outcome for patients
with and without pre-existing diabetes, was prespecified. This was exam-
ined by adding a diabetes-by-treatment interaction term to the model.
Sensitivity analyses were performed for the primary outcome (see
Appendix E1).
Further detail on the statisticalmethodologyused is given inAppendixE1.RESULTS
Patient Recruitment
Patients were recruited from February 2007 to September
2009; 191 patients were enrolled, with 95 being allocated to
ThoraCAB and 96 to OPCAB (Figure 1).Protocol Violations
There were 20 protocol violations in 18 patients. Eight
patients allocated to ThoraCAB had operations via OPCAB
and 1 patient allocated to OPCAB had the operation via
ThoraCAB. There were 11 conversions to on-pump surgery,
2 in the ThoraCAB group and 9 in the OPCAB group. Rea-
sons for these protocol violations are given in Appendix E1.
One patient, randomized to OPCAB, withdrew 3 days after
surgery but agreed to the data being used.Baseline Characteristics and Operative Details
Patient demographics and operative characteristics are
presented inTable 1. Thedurationof surgerywas, on average,
50 minutes longer for patients in the ThoraCAB group and
fewer patients in theThoraCABgrouphadmore than 3 grafts.Numbers Analyzed
Of the 191 patients enrolled, 184 were included in the
analyses. Reasons for exclusion included the following:
the surgery was postponed and they were subsequently
transferred to a surgeon not participating in STET
(n ¼ 2), additional left ventricular remodeling was required
(n ¼ 2), and no trial data were submitted (n ¼ 3).Primary Outcome
In the OPCAB group 77% of patients were classified as
fit at or before hospital discharge compared with 68% in the
ThoraCAB group. For the remaining patients the time to fit-
ness was censored. The observed median time from surgery
to fitness for discharge was 6 days (interquartile range, 4-7
days) in the ThoraCAB group versus 5 days (interquartile
range, 4-7 days) in the OPCAB group. The estimated time
ratio (TR; ThoraCAB/OPCAB) was 1.03 (95% CI,
0.94-1.14; P ¼ .53), suggesting the time until fit for dis-
charge was on average 3% longer in the ThoraCAB group.ery c August 2013
Patients considered for inclusion in trial (n=465)
(UK 412, Italy 53)
Allocated to OPCAB (n=96)
(UK 69, Italy 27)
Included in main analyses (n=93)
(UK 67, Italy 26)
Received the allocation (n=92)
Did not receive the allocation (n=1)
Received on pump surgery (n=9)
Withdrew consent from trial (n=1)
Included in main analyses (n=91)
(UK 67, Italy 24)
Received the allocation (n=83)
Did not receive the allocation (n=8)2
Received on pump surgery (n=2)2
Withdrew consent from trial (n=0)
Randomised (n=191)
(UK 138, Italy 53)
Allocated to ThoraCAB (n=95)












Randomised in error (n=2) 
No data collected (n=1)
Excluded (n=4):
Randomised in error (n=2) 
No data collected (n=2)
Patients excluded (n=274)
Ineligible (n=66)1:
Patient over 80 years (2), participating surgeon unwilling to perform surgery 
via either procedure (49), planned operation urgent or via on-pump surgery 
(6), previous cardiac surgery (3), previous lung surgery (5), participating in 
another clinical trial (6)
Not approached (n=79):
Operation cancelled (9), surgery transferred to another surgeon’s list (32), 
staff not available (15), not enough time to approach pre-surgery (9), didn’t 
receive patient information sheet (3), language barrier (3), misc/other
reason (8)
Did not consent (n=99):
Lack of time (5), wanted standard procedure (20), didn’t want two scars (3), 
language barrier (2), anxious/worried (3), personal reasons (41) 
unwilling/other reason (25)





















FIGURE 1. Flow diagram of the progress through the phases of the trial. Notes: (1) Some patients were ineligible for more than 1 reason. (2) The 2 patients
who received on-pump surgery also did not receive their treatment allocation. (3) Only patients from the United Kingdom (UK) are included in these cohorts.
ThoraCAB, Off-pump coronary artery bypass surgery via a left anterolateral thoracotomy; OPCAB, off-pump coronary artery bypass surgery via a median
sternotomy; PFT, pulmonary function test; CROQ, Coronary Revascularization Outcome Questionnaire
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DFigure 2, A, shows the time to fitness for discharge by treat-
ment group.
Secondary Outcomes
Postoperative clinical outcomes. Secondary clinical out-
comes are reported in Table 2. The intubation time wasThe Journal of Thoracic and Cashorter, by on average 65 minutes, for patients in the Thor-
aCAB group, although the time in intensive care and in the
hospital was similar (Figure 2, B and C) There were fewer
arrhythmias in the ThoraCAB group, but other complica-
tions occurred with similar frequency. Total mediastinal
fluid loss was on average 30% higher in the ThoraCABrdiovascular Surgery c Volume 146, Number 2 309
TABLE 1. Patient demography, history, and operative data
Randomized to ThoraCAB (n ¼ 91) Randomized to OPCAB (n ¼ 93) Overall (n ¼ 184)
n % n % n %
Demography
Age (y)
Mean (SD) 63.1 (8.7) 66.7 (8.0) 64.9 (8.5)
Sex
Male 84 92 80 86 164 89
BMI
Mean (SD) 27.6 (4.1) 28.0 (3.9)z 27.8 (4.0)
Cardiac history
NYHA
I/asymptomatic 48 53 44y 48 92 51
II 29 32 35 38 64 35
III 12 13 10 11 22 12
IV 2 2 2 2 4 2
CCS
No angina 16 18 10y 11 26 14
I 16 18 14 15 30 16
II 37 41 41 45 78 43
III 18 20 17 19 35 19
IV 4 4 9 10 13 7
Q-wave myocardial infarction 27 30 26z 29 53 29
Congestive cardiac failure 1 1 0y 0 1 1
Concomitant valvular disease 0 0 0y 0 0 0
Other cardiac history 7 8 0y 0 7 4
Heart rhythm
Sinus 89* 99 89* 97 178 98
Family history 55 60 47x 53 102 57
Left ventricular function
Good 72* 80 69y 76 141 78
Moderate 17 19 18 20 35 19
Poor 1 1 4 4 5 3
No. of vessels
Triple 60 66 59 63 119 65
LMS disease
>50% stenosis 29* 32 43* 47 72 40
Euroscore
Median (IQR) 3 (1, 4)* 3 (2, 4)jj 3 (2, 4)
Noncardiac history
Smoking status
No 36 40 35z 39 71 39
Ex-smoker>1 mo 36 40 42 47 78 43
Yes 19 21 13 14 32 18
Diabetes 20 22 24 26 44 24
Hypertension 66 73 75y 82 141 77
Hypercholesterolemia 77 85 72z 80 149 82
Hypothyroidism 2 2 7x 8 9 5
Peptic ulcer 2 2 3z 3 5 3
CVA/TIAs 4 4 2 2 6 3
Peripheral vascular disease 2 2 6x 7 8 4
Other medical condition 35y 39 27x 30 62 35
Operative priority
Urgent 20 22 28y 31 48 26
(Continued)
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Randomized to ThoraCAB (n ¼ 91) Randomized to OPCAB (n ¼ 93) Overall (n ¼ 184)
n % n % n %
Preoperative Tests
Creatinine (mmol/L)
Mean (SD) 92.9 (18.5)jj 93.1 (27.1)x 93.0 (23.2)
Hemoglobin (g/dL)
Mean (SD) 14.4 (3.1)y 13.9 (1.5)z 14.1 (2.5)
Platelets (3109/L)
Mean (SD) 236 (62)y 241 (73)z 239 (68)
Oxygen saturation (%)
Median (IQR) 97.0 (96, 98){ 97.5 (96, 98){ 97 (96, 98)
Mobility
Able to walk 70 m 68# 99 64# 89 132 94
Drugs on admission
Diuretics 19y 21 14y 15 33 18
Beta-blockers 75 82 66y 73 141 77
Calcium antagonists 36z 41 36y 40 72 40
Oral nitrates 16 18 18z 20 34 19
Heparin until operation 22 24 25y 27 47 26
ACE inhibitor 58 64 55y 60 113 62
Statins 81 89 79y 87 160 88
Aspirin 75 82 83z 92 158 87
Days preoperative aspirin stopped
Median (IQR) 3 (1, 6)* 2 (1, 5) 3 (1, 5)
Clopidogrel 18 20 22y 24 40 22
Days preoperative clopidogrel stopped
Median (IQR) 8 (6, 11) 7 (3, 8) 7 (5, 10.5)
Other drugs 45* 50 52y 57 97 54
Operative data in theater
Operation duration (h)
Median (IQR) 4.1 (3.5, 4.7) 3.3 (3.0, 4.0) 3.7 (3.2, 4.5)
No. of grafts
1 3z 3 4* 4 7 4
2 41 47 41 45 82 46
3 42 48 31 34 73 41
>3 2 2 16 17 18 10
Lowest core temperature (C)
Mean (SD) 35.3 (0.61) 35.1 (0.83)y 35.2 (0.73)
Lowest hematocrit (%)
Mean (SD) 35.9 (4.5)y 34.1 (5.8)y 35.0 (5.3)
Tranexamic acid 72 79 73y 80 145 80
Cell salvage 54 59 43z 48 97 54
Red blood cell transfusion** 0 0 2y 2 2 1
Other blood productsyy 1 1 0y 0 1 1
Arrythmias on chest closurezz 2y 2 1z 1 3 2
Defibrillation 4 4 3y 3 7 4
Pacing 1 1 0y 0 1 1
Inotropes (including norepinephrine) 3 3 5y 5 8 4
Vasodilators 7 8 21y 23 28 15
IABP 1 1 1y 1 2 1
On return to intensive care unit
Temperature (C)
Mean (SD) 35.9 (0.96) 35.7 (0.74) 35.8 (0.86)
(Continued)
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Randomized to ThoraCAB (n ¼ 91) Randomized to OPCAB (n ¼ 93) Overall (n ¼ 184)
n % n % n %
Hematocrit (%)
Mean (SD) 35.6 (4.9) 32.3 (4.4)* 33.9 (4.9)
Lactate (mmol/L)
Median (IQR) 1.1 (0.9, 1.5) 1.3 (1.0, 1.7)* 1.2 (0.9, 1.6)
First 24 hours postoperatively
Nadir hemoglobin (g/dL)
Mean (SD) 11.3 (1.5) 10.7 (2.1)y 11.0 (1.8)
Nadir hematocrit (%)
Mean (SD) 33.7 (4.6) 31.2 (4.5) 32.4 (4.7)
Nadir MABP (mm Hg)
Mean (SD) 64.7 (12.4) 64.2 (11.3) 64.5 (11.8)
Highest lactate (mmol/L)
Median (IQR) 1.8 (1.4, 2.4) 1.9 (1.4, 2.5) 1.8 (1.4, 2.5)
ThoraCAB,Off-pump coronary artery bypass surgery via a left anterolateral thoracotomy; OPCAB, off-pump coronary artery bypass surgery via a median sternotomy; SD, stan-
dard deviation; BMI, body mass index; NYHA, New York Heart Association; CCS, Canadian Cardiovascular Society; LMS, left main stem; IQR, interquartile range; CVA, ce-
rebrovascular accident; TIA, transient ischemic attack; ACE, angiotensin-converting enzyme; IABP, intra-aortic balloon pump; MABP, mean arterial blood pressure. *One
patient with missing data. yTwo patients with missing data. zThree patients with missing data. xFour patients with missing data. jjFive patients with missing data. {Missing
for 65 in ThoraCAB group and 63 in OPCAB group (not collected for earlier part of trial). #Missing for 22 in ThoraCAB group and 21 in OPCAB group (not collected at Italian
center for earlier part of trial). **Both patients received 2 units. yyOne patient received fresh frozen plasma (2 units). zzAll arrhythmias were atrial fibrillation.
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Dgroup. This was related to the paravertebral block inasmuch
as drainage invariably stopped once the anesthetic infusion
was discontinued.
Adverse events. The frequencies of adverse events were
similar in the 2 groups (Tables E1-E3). There were 2
deaths in the OPCAB group after discharge from the
hospital. There were 2 unexpected serious adverse events
in patients given ThoraCAB, which were classified as
related to the trial intervention. These were a left heart
hernia through the thoracotomy wound requiring repair
(definitely related) and an acute type A aortic dissection
(probably related).
Pain relief and pain scores. On average, the duration of
patient-controlled analgesia was 37% longer for patients
in the ThoraCAB group, but the total administered dose
was similar (Table 2). Complications related to paraverte-
bral block were rare (11 cases, Table E4). Pain scores re-
duced over time and were similar in the 2 groups (Table 2).
Pulmonary function tests. At hospital discharge, both the
mean FEV1 and mean FVC were higher in the OPCAB
group, but the peak expiratory flow and FEV1/FVC ratio
were similar (Table 3).
Biochemical inflammatory markers. For IL-6, lower av-
erage concentrations in the ThoraCAB group were observed
at 4 hours (ratio, 0.72; 95% CI, 0.53-0.99; P ¼ .05), but at
other time points the response was similar. For IL-8, the re-
sponse was, on average, 18% lower in the ThoraCAB group
(ratio, 0.82; 95% CI, 0.68-0.99; P ¼ .044) while for IL-10
and C5a the response was similar (ratio, 1.04; 95% CI,
0.80-1.35; P ¼ .77; and ratio, 1.09; 95% CI, 0.97-1.22;
P ¼ .12, respectively). For C3a, the treatment effect varied
with time, but there was no significant difference between
the groups at any individual time point (Table E5).312 The Journal of Thoracic and Cardiovascular SurgHospital resource use and costs. On average, the cost of
ThoraCAB was approximately 10% higher than the cost
of OPCAB (ratio, 1.10; 95% CI, 1.02-1.18; P ¼ .007;
Table E6). This was due to longer operation times, more re-
operations, and the higher cost of hospital readmissions.
Quality of life scores. On all scales (core total centred on
50 with an SD of 10; scores for all other dimensions scaled
from 0 to 100), higher scores indicated better quality of life.
Scores did not differ significantly between the groups and
there was no evidence of treatment-by-time interactions
(Table E7). The average difference in core total score be-
tween the ThoraCAB and OPCAB groups was 0.47
(95% CI,1.94 to 0.99; P ¼ .52).
Sensitivity Analyses of Time Until Fit for Discharge
The sensitivity analyses did not alter the conclusion (see
Appendix E1).
Subgroup Analysis of Fitness for Discharge
The data suggested a potentially greater treatment differ-
ence in favor of OPCAB for the subgroup with pre-existing
diabetes (TR, 1.19; 95% CI, 0.97-1.46; P ¼ .093) than for
the nondiabetic subgroup (TR, 0.99; 95% CI, 0.89-1.11;
P ¼ .86), but the interaction of diabetes with treatment
was not statistically significant (P ¼ .12).
DISCUSSION
Main Findings
In this 2-center RCT, ThoraCAB was not associated with
a reduced time until fit for hospital discharge relative to OP-
CAB. The benefits of ThoraCAB, including reduced levels
of proinflammatory cytokines, earlier extubation, and fewer
postoperative arrhythmias, were offset by longer operationery c August 2013
FIGURE 2. Time from surgery to (A) fitness for discharge, (B) discharge
from intensive treatment unit (ITU), and (C) discharge from hospital. Thor-
aCAB, Off-pump coronary artery bypass surgery via a left anterolateral
thoracotomy; OPCAB, off-pump coronary artery bypass surgery via a me-
dian sternotomy.
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sia requirements, significantly worse lung function at dis-
charge, a higher reoperation rate (4 vs 0 cases), andThe Journal of Thoracic and Caincreased cost. The only in-hospital death was also in the
ThoraCAB group. The benefits previously reported with
ThoraCAB in observational studies were not replicated in
STET, but patients in the 2 groups had comparable quality
of life at 12 months, and our data suggest that ThoraCAB
is not obviously unsafe or inferior to OPCAB.
Limitations
The relatively small study size with only 3 surgeons par-
ticipating represents a potential limitation. The study was
powered to detect a 2-day difference in the primary out-
come; it was not powered to detect the smaller difference
observed, nor was it powered to detect differences in sec-
ondary outcomes. Only 1 OPCAB patient had a deep sternal
wound infection, which was consistent with the reported
0.88% incidence rate,22 so that one of the main proposed
benefits of avoiding sternotomywas not evident. Such a ben-
efit may be detected by a larger study or in a cohort at
greater risk for sternal infection, but this was not supported
by our data, which suggested a potentially greater differ-
ence in recovery time in favor of OPCAB for the patients
with pre-existing diabetes. In addition, our results are un-
likely to be altered substantially by a larger study because
ThoraCAB had both advantages and disadvantages. Also,
reductions in markers of the inflammatory response, a major
determinant of postoperative outcome, were relatively
small. The 18% reduction in IL-8 with ThoraCAB contrasts
with an approximate 40% reduction observed in trials of
OPCAB versus CABG with CPB,18 where modest reduc-
tions in morbidity and resource use were evident.
The lack of masking was unavoidable but represents an-
other limitation. To overcome this we adopted a definition
of recovery based on objective criteria commonly used in
making discharge decisions. A significant proportion of pa-
tients were discharged before all the criteria were met, and
this was most prevalent in the ThoraCAB group, where the
median postoperative hospital stay was shorter. This sug-
gests either a possible bias on the part of attending clinicians
or that the criteria used may not have adequately character-
ized clinicians’ decisions. However, our conclusion that
there was no difference in time to recovery or to discharge
was supported by the majority of patients in both groups
that believed the discharge decision was ‘‘about right.’’
The change to our definition of the primary end point part
way through the trial is also a limitation. However, we do
not believe that our imputation using time to hospital dis-
charge for the Italian patients, for whom the additional
data could not be retrieved retrospectively, biases our find-
ings inasmuch as our conclusion was unchanged when these
patients were excluded in a sensitivity analysis.
Resource Use
ThoraCAB patients were extubated earlier, an advantage
observed to a greater extent in other series,14 but this did notrdiovascular Surgery c Volume 146, Number 2 313
TABLE 2. Secondary clinical outcomes
Randomized to
ThoraCAB (n ¼ 91)
Randomized to
OPCAB (n ¼ 93)
Effect (95% CI)
P
valuen % n %
Length of hospital stay (d)*
Median (IQR) 5 (5, 6) 6 (5, 7) TR 0.94 (0.86, 1.02) .16
Length of intensive care unit stay (h)
Median (IQR) 22.4 (18.2, 25.2) 23.0 (19.5, 26.4) HR 0.98 (0.73, 1.33) .91
Intubation time (min)*
Median (IQR) 256 (115, 464) 321 (194, 509) TR 0.75 (0.60, 0.95) .017
Death in hospital 1 1 0 0
Participants’ judgment about readiness for dischargey
Too soon 1 1 1 1 OR 0.53 (0.22, 1.30) .16
About right 69 82 64 76
Could have been earlier 9 11 17 20
Not sure 5 6 2 2
Perioperative myocardial infarctionz 4 4 1 1
Cardiac arrestx 0 0 0 0
Hemodyamic support 40 44 36 39 OR 1.28 (0.67, 2.43) .45
Arrhythmiasx 21 23 32 35 OR 0.52 (0.26, 1.03) .059
Pulmonary complicationsx 13 14 9 10 OR 1.56 (0.62, 3.90) .34
Renal complicationsx 0 0 0 0
Infective complicationsjj 10 11 10 11 OR 1.02 (0.40, 2.58) .97
Gastrointestinal complicationsx 2 2 1 1
Neurologic complicationsx 1 1 1 1
Reoperation{ 4 4 0 0
Blood loss in first 12 hours#
GM 449 404 GMR 1.10 (0.97, 1.26) .13
Total mediastinal fluid loss**
GM 856 649 GMR 1.31 (1.15, 1.49) <.001
Red blood cell transfusion after surgeryyy 7 8 12 13 OR 0.55 (0.20, 1.51) .24
If yes, units transfused
Median (IQR) 3 (1, 3) 2 (1, 3)
Other transfusion after surgeryzz 5 5 2 2
Activated factor VII used after surgery?xx 0 0 0 0
Asepsis score>20 (any wound)
Before discharge 0 0 1 1
Six weeks after dischargejjjj 8 13 7 11 OR 1.16 (0.40, 3.41) .78
Pain relief
PCA duration (h)yy
Median (IQR) 38.8 (32.5, 47.2) 35.5 (24.8, 40.2) TR 1.37 (1.25, 1.49) <.0001
PCA volume (mg)xxx
GM 50.9 48.2 GMR 1.04 (0.86, 1.24) .69
Use of NSAIDszzz 16 18 9 10 OR 2.18 (0.89, 5.36) .082
Use of tramadolx 57 66 45 49 OR 2.53 (1.11, 5.76) .024
Use of codeine (or similar)jjj 11 13 9 10 OR 1.28 (0.49, 3.36) .61
Pain scores{{ (n ¼ 84) (n ¼ 89)
Two hours after extubation##
Mean (SE) 35.0 2.50 35.0 2.52
Twelve hours after extubation***
Mean (SE) 30.1 1.76 30.2 1.78
Twenty-four hours after extubationyyy
Mean (SE) 27.1 1.63 27.2 1.66
Thirty-six hours after extubationzzzz
Mean (SE) 25.1 1.56 25.1 1.59
(Continued)
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ThoraCAB (n ¼ 91)
Randomized to
OPCAB (n ¼ 93)
Effect (95% CI)
P
valuen % n %
Five days after extubationxxxx
Mean (SE) 17.8 1.73 17.8 1.75
Test for treatment time interaction .67
Overall estimate of treatment effect 0.063 (3.85, 3.72) .97
ThoraCAB, Off-pump coronary artery bypass surgery via a left anterolateral thoracotomy; OPCAB, off-pump coronary artery bypass surgery via a median sternotomy; CI, con-
fidence interval; IQR, interquartile range; TR, time ratio; HR, hazard ratio; OR, odds ratio;GM, geometric mean;GMR, geometric mean ratio; PCA, patient-controlled analgesia;
NSAIDs, nonsteroidal anti-inflammatory drugs; SE, standard error. *One outlier was excluded (OPCAB group). yComparison is ‘‘could have been earlier’’ versus ‘‘too soon’’/
‘‘about right.’’ The most commonly occurring category (‘‘about right’’) was imputed for the 16 patients (7 ThoraCAB group, 9 OPCAB group) with missing data. The same
treatment estimate and P value were obtained in a model without imputing missing data. zDefined as troponin I>0.5 mg/L and at least 1 of the following: (1) new Qs in 2 con-
tiguous leads, (2) new ST depression>2mm in 2 leads. One patient (OPCAB group) with missing data. xOne patient (OPCAB group) with missing data. jjAdjustment for surgeon
or center caused perfect prediction. Only diabetes and number of diseased vessels were adjusted for. {All reoperations occurred in the first 24 hours after surgery and were for
bleeding. Two patients (OPCAB group) with missing data. #One outlier was excluded (ThoraCAB group). **One outlier was excluded (ThoraCAB group). Three patients (1
ThoraCAB group, 2 OPCAB group) with missing data. yyTwo patients (OPCAB group) with missing data. zzOther transfusions consist of the following: ThoraCAB group: plate-
lets (n¼ 4), cryoprecipitate (n¼ 1); OPCAB group: fresh frozen plasma (n¼ 1), fresh frozen plasma and platelets (n¼ 1). Two patients (OPCAB group) with missing data. xxTwo
patients (ThoraCAB group) with missing data. jjjjData only collected for Bristol patients. Asepsis score20 (most common category) was imputed for the 12 Bristol patients (6
ThoraCAB group, 6 OPCAB group) with missing data. zzzFive patients (3 ThoraCAB group, 2 OPCAB group) with missing data. xxxFive patients (4 ThoraCAB group, 1 OPCAB
group) with missing data. jjjSeven patients (4 ThoraCAB group, 3 OPCAB group) with missing data. {{Thirteen patients had one score collected, 7 patients had two scores, 23
had three scores, 54 had four scores, and 74 had five scores. Method of pain assessment was missing for 25 observations (3.7%) on 19 individuals. The most common group
(verbal) was imputed for these observations. ##Forty-six patients (19 ThoraCAB group, 27 OPCAB group) with missing data, including 25 patients recorded as asleep (10 Thor-
aCAB group, 15 OPCAB group). ***Twenty-eight patients (11 ThoraCAB group, 17 OPCAB group) with missing data, including 10 patients recorded as asleep (4 ThoraCAB
group, 6 OPCAB group). yyyTwenty-nine patients (9 ThoraCAB group, 20 OPCAB group) with missing data, including 7 patients recorded as asleep (3 ThoraCAB group, 4
OPCAB group). zzzzForty-six patients (19 ThoraCAB group, 27 OPCAB group) with missing data, including 12 patients recorded as asleep (6 ThoraCAB group, 6 OPCAB
group). xxxxEstimates are provided at 5 days after extubation (approximate median time discharge score was done). Twenty-four patients (11 ThoraCAB group, 13 OPCAB
group) with missing data. No patients were recorded as asleep.
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(1) previous observational reports did not compare contem-
poraneous cohorts,14-16 (2) the rapid discharge protocol
advocated in these studies was not applicable to this
cohort that was, on average, 10 years older,14 (3) changing
other clinicians’ practice to extubate early was difficult and
the average time to extubation was only reduced by approx-
imately 1 hour, which is of limited clinical significance; and
(4) patient transfer to less intensive levels of care wasTABLE 3. Pulmonary function
Randomized to
ThoraCAB (n ¼ 63)
Baseline Mean SD M
FEV1 (L)* 2.84 0.69
FVC (L)y 3.56 0.76
PEF (L/m)z 379 135 37
FEV1/FVC ratio (%)x 78.9 7
Discharge Mean SE M
FEV1 (L)jj 1.48 0.10
FVC (L)jj 1.90 0.11
PEF (L/m)jj 229 21 25
FEV1/FVC ratio (%){ 78.8 7
ThoraCAB, Off-pump coronary artery bypass surgery via a left anterolateral thoracotomy;
fidence interval; SD, standard deviation; FEV1, forced expiratory volume in 1 second; FVC,
ThoraCAB group, 6 OPCAB group) with missing data. yTen patients (four ThoraCAB gr
OPCAB group) with missing data. xResults are presented as geometric means as the analys
with missing data. jjForty patients (24 ThoraCAB group, 16 OPCAB group) with missing da
OPCAB) as the analysis was performed on the log scale. Forty patients (24 ThoraCAB gr
observations on 6 individuals were excluded from this analysis (4 observations at baseline
being excluded from this analysis.
The Journal of Thoracic and Cadetermined by institutional protocols that are influenced
by postoperative organ dysfunction and nursing
requirements.
Adequacy of Revascularization
A risk attendant to the use of MIDCAB techniques is that
as invasiveness declines so too does the completeness of re-
vascularization. Fewer grafts were performed in the Thora-
CAB group despite the 2 groups being well matched in theRandomized to
OPCAB (n ¼ 64)
Mean difference
(ThoraCAB-OPCAB)







1.61 0.09 0.13 (0.28, 0.02) .09
2.15 0.11 0.25 (0.44,0.06) .01
5 21 26 (62, 11) .17
7.7 1.01 (0.96, 1.07) .58
OPCAB, off-pump coronary artery bypass surgery via a median sternotomy; CI, con-
forced vital capacity; SE, standard error; PEF, peak expiratory flow. *Nine patients (3
oup, six OPCAB group) with missing data. zEleven patients (4 ThoraCAB group, 7
is was performed on the log scale. Ten patients (4 ThoraCAB group, 6 OPCAB group)
ta. {Results are presented as geometric means and geometric mean ratios (ThoraCAB/
oup, 16 OPCAB group) with missing data. Eight (1 ThoraCAB, 7 OPCAB) outlying
and 4 observations at discharge), resulting in 2 patients (both in the OPCAB group)
rdiovascular Surgery c Volume 146, Number 2 315
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Dextent and severity of their coronary disease. This may re-
flect a learning curve with ThoraCAB. The STET surgeons
had all performed more than 30 ThoraCAB procedures be-
fore joining the trial and had extensive experience with
MICS,3,9 but nonetheless their experience with ThoraCAB
was significantly less than with OPCAB (>200
procedures). Also, ThoraCAB, unlike OPCAB, was not
available outside the trial.
CONCLUSIONS
This is the first RCT of ThoraCAB versus OPCAB. We
have demonstrated that the benefits of ThoraCAB—reduced
inflammatory response, shorter intubation times, and fewer
arrhythmias—are offset by longer operations with fewer
grafts, a greater need for postoperative pain relief, worse
lung function at discharge, and higher costs. We have also
shown that the patients’ quality of life at 12 months is sim-
ilar with the 2 procedures. Our results are at odds with the
benefits reported in observational studies; our experience
with ThoraCAB is less than with OPCAB and further eval-
uation is needed before widespread dissemination.
We thank the clinical trial coordinators and research nurses, in
particular Dr Lucy Culliford, for managing the trial and collecting
trial data; Dr Daphne Kounali and Mrs Kate Bayliss for assisting
with the statistical analysis; Dr Giuseppe Aresu, Dr Nalima Shu-
kla, and Ms Sam Passey for the biomarker analyses; and Dr Sally
Tomkins for writing the protocol for postoperative pain relief for
ThoraCAB patients.
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APPENDIX E1
Primary Outcome—Component Definitions
Infection was defined as (a) systemic lower respiratory tract
infection, comprising (i) systemic inflammatory response
syndrome (SIRS) and (ii) antibiotic treatment for suspected
or proven infection and (iii) at least one of productive
cough, new or progressive infiltrates on chest radiograph,
positive sputum culture or declining oxygenation or (b)
wound infection defined as an in-hospital ASEPSIS score
greater than 20 (each wound assessed separately)19 or (c)
sepsis that comprised (i) documented culture-positive infec-
tion or intravenous antibiotic treatment for suspected infec-
tion and (ii) SIRS.
SIRS was defined as 2 or more of the following: (i) tem-
perature>38C or<36C; (ii) heart rate>90 beats/minute;
(iii) respiratory rate <20 breaths/min or arterial carbon
dioxide tension<32 mm Hg; (iv) white blood cell count
>12,000/mm3 or<4000/mm3
Normal routine blood test results and temperature were
defined as (a) white blood cell count 4000/mm3 and
12,000/mm3 and (b) temperature 36C and 38C.
Physical fitness was defined as the ability to walk 70 m,
having an oxygen saturation on air 95%, and having
had the bowels opened.
Cost Analysis
National Health Service reference costs for 2008/2009
were used.23 Operative and ward costs were not available
for 2008/2009, so costs from earlier years24,25 inflated to
2008/2009 levels using pay and prices index figures26
were used.
Statistical Methods
For the comparison of pain scores between the OPCAB
and ThoraCAB groups, the analysis was adjusted for factors
included in the cohort minimization plus the assessment
method (visual analog scale or verbal). Also, for the analy-
sis of biomarkers, interactions of surgeon, diabetes, and
number of diseased vessels with time were considered.
Time-to-event outcomes were compared using hazard ra-
tios or time ratios (TR), depending on the model used. The
model (Cox proportional hazards or parametric accelerated
failure time) was chosen on the basis of the validity of the
model assumptions and goodness of fit, assessed graphi-
cally and using the Akaike information criterion.27 Time-
to-event curves were constructed using the Kaplan-Meier
method. Continuous outcomes were compared using a dif-
ference in means, with logarithmic transformations if distri-
butions were skewed. For transformed data, the results were
transformed back to the original scale after analysis and the
results presented as geometric means, with the treatment
difference expressed as a ratio of geometric means. Binary
outcomes were compared using odds ratios. Formal statisti-
cal comparisons are presented for binary outcomes only if
more than 10 patients experienced the outcome (with at
least 1 event in each treatment group). For multicategory
outcomes, ordinal or multinomial logistic regression was
used as appropriate. Categories were combined if fewer
than 5% of patients were in any 1 category across both
treatment groups. Repeated measures of continuous out-
comes were analyzed using the linear mixed effects meth-
odology, and where the outcome was measured both
preoperatively and postoperatively, the preoperative and
postoperative values were modeled jointly to avoid the
need to exclude or impute values for cases with missing
preoperative values. Treatment-by-time interactions were
examined where possible, and if the interaction was
statistically significant at the 10% level using a like-
lihood ratio test, changes in treatment effect with time are
described; otherwise, an overall treatment effect is reported.
Missing data in baseline characteristics are indicated by
footnotes and did not differ substantially between groups.
Missing data for outcomes compared at a single time point
were infrequent (<5%); for these outcomes, the analyses
presented use cases with complete data. The only excep-
tions to this were the patients’ judgment of readiness for dis-
charge and 6-week wound infection (both 9% missing
data), where imputation of the most common categories
was used. For longitudinal outcomes, missing data was
more common (eg, 25% of pain scores are missing). For
these analyses, variables predictive of missingness were
identified and included in the model.
Statistical tests for baseline imbalance were not carried
out inasmuch as such hypothesis testing can be
misleading.28
Mixed models were fitted in SAS version 9.2 (SAS Insti-
tute Inc, Cary, NC) andMLwin version 2.1 (Centre for Mul-
tilevel Modelling, University of Bristol, United Kingdom).
All other analyses were performed using Stata version 11.1
(StataCorp LP, College Station, Tex).
Interim Analysis
The Data Monitoring and Safety Committee periodically
reviewed the safety data and a formal interim analysis of
time until fit for discharge, total postoperative hospital
stay, and pain scores, which was performed when 50% of
patients had been recruited. The P values reported are not
corrected for this interim analysis.
Reasons for Not Receiving the Allocated Treatment
Patient request (2, one in each group), poor gas exchange
(1), severe vascular disease (1), high-risk patient (3),
poor left ventricular function (1), and ascending aortic
aneurysm (1).
Reasons for conversion to on-pump surgery were hemo-
dynamic instability/STelevation (6), unknown hemorrhagic
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pericarditis (1), intramyocardial vessels (1), severe coro-
nary calcification (1), ventricular fibrillation before grafting
(1), and not recorded (1).
Sensitivity Analyses of Time Until Fit for Discharge
Five sensitivity analyses were undertaken:
1. Test for different treatment effects at the 2 centers
(P ¼ .71)
2. Excluding protocol violations (TR, 1.04; 95% CI, 0.94,
1.15; P ¼ .48)
3. Excluding patients without mobility-related fitness data
(TR, 1.01; 95% CI, 0.91, 1.12; P ¼ .85)
4. Relaxing the assumption of a common baseline hazard
for all patients, through stratification by center (TR,
1.03; 95% CI, 0.94, 1.14; P ¼ .51)
5. Assessing the impact of possible informative censoring
by (i) assuming fitness was observed for all patients
(TR, 0.99; 95% CI, 0.91, 1.08; P ¼ .82) and (ii) assum-
ing all censored times had the longest observed time to
fitness (TR, 1.01; 95% CI, 0.92, 1.12; P ¼ .78).
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TABLE E1. Expected adverse events by treatment received: Patients who had off-pump surgery
Surgery via
ThoraCAB (n ¼ 84)
Surgery via
OPCAB (n ¼ 89) Overall (n ¼ 173)
n % n % n %
PATIENTS WITH 1 OR MORE EXPECTED EVENT 70 83 77 87 147 85
PREDISCHARGE EVENTS
Perioperative MI* 11 13 2 2 13 8
New Qs in 2 contiguous leads* 0 0 0 0 0 0
Raised troponin I (>0.5 mg/L)* 11 13 2 2 13 8
New ST depression>2 mm in 2 leads* 3 4 1 1 4 2
Cardiac arrest* 0 0 0 0 0 0
Hemodynamic support 34 40 39 44 73 42
Any inotropes (excluding norepinephrine)* 6 7 1 4 7 4
Norepinephrine used* 17 20 22 25 39 23
IABP* 0 0 1 1 1 1
Pulmonary artery catheter* 0 0 0 0 0 0
Vasodilator 17 20 17 19 34 20
Arrhythmias* 17 20 31 35 48 28
SVT/AF requiring treatment* 16 19 30 34 46 27
VF/VT requiring intervention* 2 2 2 2 4 2
Pacingy 0 0 3 3 3 2
Pulmonary complications* 11 13 11 13 22 13
Reintubation and ventilation* 3 4 3 3 6 3
Tracheostomy* 2 2 0 0 2 1
Mask CPAP* 10 12 10 11 20 12
ARDS* 0 0 0 0 0 0
Renal complications* (new hemofiltration/dialysis) 0 0 0 0 0 0
Infective complications 67 80 76 85 143 83
Septicemia* 1 1 1 1 2 1
Culture-positive sputum* 0 0 2 2 2 1
Productive coughz 38 45 37 43 75 44
Temperature>38C or<36C 9 11 12 13 21 12
White cell count>12,000 or<4000 46 55 53 60 99 57
Raised CRP (>100) 58 69 68 76 126 73
New/progressive radiographic infiltrates on chest x-ray film 11 13 9 10 20 12
Heart rate>90 beats/min* 47 56 52 59 99 58
Respiratory rate>20 breaths/min or PaCO2<32 mm Hg 49 58 51 57 100 58
IV antibiotics* 6 7 12 14 18 10
Oral antibiotics* 8 10 8 9 16 9
GI complications* 2 2 1 1 3 2
Peptic ulcer/GI bleed/perforation* 1 1 1 1 2 1
Pancreatitis* 0 0 0 0 0 0
Other (eg, laparotomy, obstruction)* 1 1 0 0 1 1
Neurologic complications* 1 1 1 1 2 1
Stroke* 0 0 0 0 0 0
Coma or confusion state* 1 1 1 1 2 1
TIA* 0 0 0 0 0 0
Reoperationx 3 4 1 1 4 2
Death before discharge 1 1 0 0 1 1
POSTDISCHARGE EVENTS
Possibly related 2 2 1 1 3 2
Stroke resulting in readmission and subsequent death 0 1 1
Readmission with ventricular tachycardia; ICD inserted
Further readmissions with ICD problems and arrhythmias 1 0 1
Wound infection requiring readmission 1 0 1
(Continued)
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ThoraCAB (n ¼ 84)
Surgery via
OPCAB (n ¼ 89) Overall (n ¼ 173)
n % n % n %
Probably related 1 1 0 0 1 1
Wound infection requiring readmission 1 0 1
Unrelated 0 0 3 3 3 2
Chest infection/pneumonia requiring readmission
Respiratory failure resulting in death 0 1 1
Readmitted for drainage of large left pleural effusion
Discharged home after 5 d after removal of drain 0 1 1
Repeat admissions to A&E with pericardial effusion and left pleural effusion
Undergoing follow-up outpatient appointments with cardiologist 0 1 1
Relationship unknown 2 2 5 6 7 4
Leg infection 0 1 1
Septic leg 1 0 1
Arrhythmia 1 0 1
Pleural effusion 0 1 1
TIA 0 1 1
Wound infectionjj 0 1 1
Sternum infection/not healing 0 1 1
Each bold event is composed of the events listed below it. A patient can experience more than 1 of the component events. ThoraCAB,Off-pump coronary artery bypass surgery via
a left anterolateral thoracotomy; OPCAB, off-pump coronary artery bypass surgery via a median sternotomy; MI, myocardial infarction; IABP, intra-aortic balloon pump; SVT,
supraventricular tachycardia; AF, atrial fibrillation; VF, ventricular fibrillation; VT, ventricular tachycardia; CPAP, continuous positive airway pressure; ARDS, acute respiratory
distress syndrome; CRP, C-reactive protein; Paco2, arterial carbon dioxide tension; IV, intravenous; GI, gastrointestinal; TIA, transient ischemic attack; ICD, implantable cardi-
overter defibrillator; A&E, accident and emergency. *One patient (OPCAB group) with missing data. yPacing was permanent for 1 patient in the OPCAB group (status unknown
for the remaining 2 patients). One patient (OPCAB group) with missing data. zTwo patients (both OPCAB group) with missing data. xAll reoperations occurred in the first 24
hours after surgery and were for bleeding. Two patients (both OPCAB group) with missing data. jjPatient admitted twice for this reason.
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TABLE E2. Expected adverse events by treatment received: Patients who had on-pump surgery
Surgery via ThoraCAB (n ¼ 0) Surgery via OPCAB (n ¼ 11)
n % n %
PATIENTS WITH 1 OR MORE EXPECTED EVENT 7 64
PREDISCHARGE EVENTS
Perioperative MI 2 18
New Qs in 2 contiguous leads 1
Raised troponin I (>0.5 mg/L) 2
New ST depression>2 mm in 2 leads 0
Cardiac arrest 0 0
Hemodynamic support 3 27
Any inotropes (excluding norepinephrine) 3
Norepinephrine used 2
IABP 1
Pulmonary artery catheter 1
Vasodilator 0
Arrhythmias 5 45
SVT/AF requiring treatment 5
VF/VT requiring intervention 1
Pacing 0
Pulmonary complications 0 0




Renal complications (new hemofiltration/dialysis) 0 0





White cell count>12,000 or<4,000 6
Raised CRP (>100) 2
New/progressive radiographic infiltrates on chest radiograph 0
Heart rate>90 beats/min 2
Respiratory rate>20 breaths/min or PaCO2<32 mm Hg 2
IV antibiotics 1
Oral antibiotics 0
GI complications 0 0
Peptic ulcer/GI bleed/perforation 0
Pancreatitis 0
Other (eg, laparotomy, obstruction) 0
Neurologic complications 0 0
Stroke 0
Coma or confusion state 0
TIA 0
Reoperation 0 0
Death before discharge 0 0
POSTDISCHARGE EVENTS
Relationship unknown 1 0
Pleural effusion, suspected heart attack 1
Each bold event is composed of the events listed below it. A patient can experience more than 1 of the component events. ThoraCAB,Off-pump coronary artery bypass surgery via
a left anterolateral thoracotomy; OPCAB, off-pump coronary artery bypass surgery via a median sternotomy; MI, myocardial infarction; IABP, intra-aortic balloon pump; SVT,
supraventricular tachycardia; AF, atrial fibrillation; VF, ventricular fibrillation; VT, ventricular tachycardia; CPAP, continuous positive airway pressure; ARDS, acute respiratory
distress syndrome; CRP, C-reactive protein; Paco2, arterial carbon dioxide tension; IV, intravenous; GI, gastrointestinal; TIA, transient ischemic attack; ICD, implantable cardi-
overter defibrillator; A&E, accident and emergency.
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TABLE E3. Unexpected adverse events by treatment received
Patients who had off-pump surgery*
Surgery via
ThoraCAB (n ¼ 84)
Surgery via
OPCAB (n ¼ 89) Overall (n ¼ 173)
Patients with 1 or more unexpected event 10 (12%) 7 (8%) 17 (10%)
Definitely related 1 0 1
Left heart hernia through thoracotomy wound requiring readmission
Ventricular hernia repair via thoracotomy and sternotomy 1 0 1
Probably related 1 0 1
Hemothorax requiring readmission, clot and type A aortic
dissection, bilateral effusions, h
ematoma in right ventricle, renal failure
1 0 1
Unlikely to be related 1 0 1
Readmission for chest pain and shortness of breath. Investigations
could not find likely cause. Discharged after 26 d after prescription
of anxiety drugs
1 0 1
Unrelated 3 0 3
Readmitted for lead replacement to ICD 1 0 1
Readmission owing to pain at ICD site 1 0 1
Delayed reaction to antibiotics causing rash and pyrexia 1 0 1
Relationship unknown 4 7 11
Chest pain—not cardiac 1 0 1
Hernia 0 1 1
Pleurisy 0 1 1
Sternum—wiring/clip problems 0 1 1
Chest pain 1 0 1
ECG, 24 h 0 1 1
Shortness of breath, chest radiographsy 1 0 1
Pneumonia 1 0 1
Chest pain, blood pressure monitor for 24 hy 0 1 1
Thrombosis/embolism 0 1 1
Irregular heartbeat 0 1 1
ThoraCAB, Off-pump coronary artery bypass surgery via a left anterolateral thoracotomy; OPCAB, off-pump coronary artery bypass surgery via a median sternotomy; ICD,
implantable cardioverter defibrillator; ECG, electrocardiogram. *There were no events in patients who had on-pump surgery (n¼ 11). yEach of these patients was admitted twice
for the same reason.
TABLE E4. Pain relief —additional information (ThoraCAB patients
only)
Randomized to
ThoraCAB (n ¼ 91)
n %
PV block volume in first 24 h
Median (IQR) mL 234 (90, 250)
PV block volume overall
Median (IQR) mL 360 (95, 520)
PV block complications
Cardiac arrest* 0 0
Convulsions without cardiac arrest* 1 1
Persistent hypotension* 1 1
PV block failurey 9 11
ThoraCAB,Off-pump coronary artery bypass surgery via a left anterolateral thoracot-
omy; PV, paravertebral; IQR, interquartile range. *Twenty-two patients with missing
data. yOf the patients with PV block failure, 6 had at least one bolus, 1 had an inter-
costal block, 4 had nurse-administered intravenous morphine, and none had diclofe-
nac, intravenous ketamine, clonidine, or any other pain relief. Eleven patients have
missing data.
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TABLE E5. Biochemical inflammatory markers
Variable (log-scale)
Randomized to
ThoraCAB (n ¼ 30)
Randomized to
OPCAB (n ¼ 27)
Mean difference
(ThoraCAB-OPCAB) (95% CI) GMR (95% CI)
P
value
Baseline Mean SD Mean SD
IL-6 (pg/mL)* 1.17 0.64 1.35 0.93
IL-8 (pg/mL)y 1.96 0.51 2.01 0.46
IL-10 (pg/mL)z 2.14 0.52 2.10 0.49
C3a (ng/mL)x 7.74 0.30 7.52 0.50
C5a (ng/mL)jj 2.76 0.40 2.62 0.42
After intervention Mean SE Mean SE
IL-6 (pg/mL) (n ¼ 29) (n ¼ 27)
End of surgery{ 5.29 0.24 5.10 0.25 0.19 (0.22,0.59) 1.21 (0.80, 1.80)
Four hours after surgery# 5.66 0.19 6.00 0.19 0.33 (0.64,0.01) 0.72 (0.53, 0.99)
Twelve hours after surgery** 5.79 0.25 5.85 0.25 0.06 (0.49, 0.38) 0.94 (0.61, 1.46)
Twenty-four hours after surgeryyy 5.80 0.22 5.84 0.22 0.04 (0.41,0.33) 0.96 (0.66, 1.39)
Test for treatment time interaction .013
IL-8 (pg/mL) (n ¼ 29) (n ¼ 27)
End of surgery** 2.91 0.17 3.08 0.17
Four hours after surgeryzz 3.34 0.15 3.52 0.15
Twelve hours after surgery** 3.61 0.17 3.62 0.17
Twenty-four hours after surgery# 3.37 0.17 3.64 0.17
Test for treatment time interaction .12
Overall estimate of treatment effect 0.19 (0.38,0.004) 0.82 (0.68, 0.99) .044
IL-10 (pg/mL) (n ¼ 26) (n ¼ 25)
End of surgery** 2.66 0.27 2.34 0.28
Four hours after surgeryzz 2.86 0.23 2.72 0.24
Twelve hours after surgery** 2.97 0.22 3.09 0.23
Twenty-four hours after surgery# 2.98 0.26 3.07 0.27
Test for treatment time interaction .23
Overall estimate of treatment effect 0.04 (0.22, 0.30) 1.04 (0.80, 1.35) .77
C3a (ng/mL) (n ¼ 30) (n ¼ 27)
End of surgery** 7.74 0.12 7.61 0.13 0.13 (0.08,0.33) 1.14 (0.92, 1.39)
Four hours after surgeryzz 7.52 0.12 7.41 0.12 0.11 (0.10,0.31) 1.12 (0.90, 1.36)
Twelve hours after surgery** 7.40 0.12 7.56 0.12 0.17 (0.35,0.01) 0.84 (0.70, 1.01)
Twenty-four hours after surgeryjj 7.62 0.13 7.75 0.13 0.13 (0.34,0.08) 0.87 (0.71, 1.08)
Test for treatment $time interaction .007
C5a (ng/mL) (n ¼ 30) (n ¼ 27)
End of surgeryjj 2.64 0.12 2.58 0.13
Four hours after surgery 2.85 0.11 2.73 0.12
Twelve hours after surgery 2.90 0.12 2.81 0.12
Twenty-four hours after surgery 3.10 0.13 3.02 0.13
Test for treatment $time interaction .70
Overall estimate of treatment effect 0.09 (0.03, 0.20) 1.09 (0.97, 1.22) .12
ThoraCAB, Off-pump coronary artery bypass surgery via a left anterolateral thoracotomy; OPCAB, off-pump coronary artery bypass surgery via a median sternotomy; GMR,
geometric mean ratio; CI, confidence interval; SD, standard deviation; IL, interleukin; C, complement. *Six patients (2 ThoraCAB group, 4 OPCAB group) with missing
data. ySix patients (1 ThoraCAB group, 5 OPCAB group) with missing data. zEleven patients (5 ThoraCAB group, 6 OPCAB group) with missing data. xSeven patients (1 Thor-
aCAB group, 6 OPCAB group) with missing data. jjOne patient (OPCAB group) with missing data. {Three patients (OPCAB group) with missing data. #Two patients (1 Thor-
aCAB group, 1 OPCAB group) with missing data. **Two patients (OPCAB group) with missing data. yyTwo patients (ThoraCAB group) with missing data. zzThree patients (2
ThoraCAB group, 1 OPCAB group) with missing data.
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TABLE E6. Hospital resource use and costs
Randomized to ThoraCAB (n ¼ 91): GM Randomized to OPCAB (n ¼ 93): GM Effect (95% CI) P value
Total cost* £5079 £4566 GMR 1.10 (1.02, 1.18) .007
Operation cost £2363 £1987
Reoperation costy £869 £0
Intensive care unit cost £1411 £1430
High dependency unit cost £831 £613
Ward cost £293 £381
Readmission costz £888 £428
ThoraCAB, Off-pump coronary artery bypass surgery via a left anterolateral thoracotomy; OPCAB, off-pump coronary artery bypass surgery via a median sternotomy; CI, con-
fidence interval; GM, geometric mean; GMR, geometric mean ratio. *Three outliers were excluded from model (2 ThoraCAB group, 1 OPCAB group). yFour patients had a re-
operation (all ThoraCAB group). zTwenty three patients were readmitted in the first postoperative year (10 ThoraCAB group, 13 OPCAB group).
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TABLE E7. Quality of life scores (Coronary Revascularization Outcome Questionnaire)
Randomized to ThoraCAB (n ¼ 66) Randomized to OPCAB (n ¼ 66) Effect (95% CI) P value
Baseline n Mean SD n Mean SD
Core total 62 49.7 6.12 63 50.2 6.73
Symptoms 63 74.5 19.6 63 73.8 21.7
Physical functioning 62 72.9 26.1 63 69.0 28.3
Psychosocial functioning 62 65.7 21.8 63 70.0 23.9
Cognitive functioning 62 79.5 23.0 63 82.9 25.2
Follow-up n Mean SE Mean SE
Core total*
Three months 53 48.3 1.13 50 48.9 1.17
Twelve months 56 48.7 1.14 54 49.1 1.18
Test for treatment time interaction .81
Overall estimate of treatment effect 0.47 (1.94, 0.99) .52
Symptomsy
Three months 53 91.5 1.83 50 92.1 1.93
Twelve months 56 95.0 1.48 54 96.9 1.63
Test for treatment time interaction .51
Overall estimate of treatment effect 1.64 (3.88, 0.59) .15
Physical functioningz
Three months 53 84.6 3.96 50 87.3 4.17
Twelve months 55 94.5 3.65 54 91.6 3.89
Test for treatment time interaction .12
Overall estimate of treatment effect 1.26 (3.98, 6.51) .63
Psychosocial functioningx
Three months 53 74.0 3.18 50 74.7 3.30
Twelve months 56 84.8 2.58 54 85.7 2.81
Test for treatment time interaction .95
Overall estimate of treatment effect 0.83 (4.63, 2.97) .66
Cognitive functioningjj
Three months 53 81.7 3.43 50 81.6 3.59
Twelve months 54 87.9 2.93 54 89.2 3.19
Test for treatment time interaction .67
Overall estimate of treatment effect 0.96 (5.25, 3.32) .65
Satisfaction{
Three months 51 81.6 3.05 50 82.9 3.32
Twelve months 55 82.7 3.07 54 87.7 3.38
Test for treatment time interaction .15
Overall estimate of treatment effect 3.21 (8.19, 1.77) .20
Adverse events#
Three months 51 80.4 2.37 50 81.5 2.58
Twelve months 55 89.4 2.40 54 88.7 2.62
Test for treatment time interaction .40
Overall estimate of treatment effect 0.17 (4.01, 3.67) .93
The number of observations varies slightly between different scores owing to insufficient data being available to calculate scores for a small number of observations. ThoraCAB,
Off-pump coronary artery bypass surgery via a left anterolateral thoracotomy;OPCAB, off-pump coronary artery bypass surgery via a median sternotomy;CI, confidence interval;
SD, standard deviation; SE, standard error. *Three outliers were excluded for 12-month scores (1 in ThoraCAB group, 2 in OPCAB group). A compound symmetry covariance
pattern was used. yOne outlier was excluded for 3-month scores (ThoraCAB group); 4 outliers were excluded for 12-month scores (1 in ThoraCAB group, 3 in OPCAB group). A
general (unstructured) covariance pattern was used. zNo outliers were excluded. A general (unstructured) covariance pattern was used. xTwo outliers were excluded for 12-month
scores (1 in ThoraCAB group, 1 in OPCAB group). A general (unstructured) covariance pattern was used. jjTwo outliers were excluded for 12-month scores (both in ThoraCAB
group). A general (unstructured) covariance pattern was used. {Two outliers were excluded for 3-month scores (both in ThoraCAB group); 4 outliers were excluded for 12-month
scores (2 in ThoraCAB group, 2 in OPCAB group). A compound symmetry covariance pattern was used. #Two outliers were excluded for 12-month scores (both in ThoraCAB
group). A compound symmetry covariance pattern was used.
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